EMA validates use of BAVENCIO for treating Urothelial Carcinoma
Category: #health  | By Nikita Chaurasia  | Date: 2020-06-24 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

EMA validates use of BAVENCIO for treating Urothelial Carcinoma

German multinational pharmaceutical, chemical, and life sciences company, Merck KGaA, headquartered in Darmstadt, recently declared that the European Medicines Agency (EMA) has approved the review process for the Type II variation application for BAVENCIO ® (avelumab) for first-line treatment of patients suffering with locally advanced or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.

Reportedly, results from the Phase III JAVELIN Bladder 100 study proved that BAVENCIO together with best supportive care (BSC) as a first-line maintenance treatment after induction chemotherapy showed considerable improvement in overall survival (OS) of the patients in comparison to standalone BSC.

If reports are to be believed, the supplemental Biologics License Application (sBLA) for first-line maintenance treatment of locally advanced or metastatic UC patients was given Priority Review status under the FDA’s Real-Time Oncology Review (RTOR) pilot program. BAVENCIO was also granted a Breakthrough Therapy Designation by the FDA for this indication.

Additionally, Japan's Ministry of Health, Labour and Welfare has also welcomed the supplemental new drug application for BAVENCIO as a first-line maintenance therapy for locally advanced or metastatic UC.

For the record, urothelial carcinoma accounts for 90% of bladder cancers. Besides this, about 200,000 individuals are diagnosed with bladder cancer each year in the European Union, which claims lives of more than 60,000 individuals annually. 

Previously, Merck’s Keytruda (pembrolizumab) drug combined with platinum-based chemo for untreated advanced UC didn’t prove effective for patients whose disease had spread to other body parts. Keytruda is already approved as a first-line treatment for UC patients who can’t endure cisplatin-based chemotherapy, but the failed results from the KEYNOTE-361 trail has prevented the drug’s enhanced use in these patients.

Although Keytruda couldn’t pass the trails, Merck’s BAVENCIO has exhibited potential in reducing the increasing burden of UC.

Source: https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior

https://www.pmlive.com/pharma_news/failed_trial_dashes_mercks_hopes_for_keytruda_in_first-line_bladder_cancer_1341996

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Goldman Sachs provides unlimited holidays to its senior employees

Goldman Sachs provides unlimited holidays to its senior employees

By Nikita Chaurasia

Goldman Sachs has recently announced a flexible vacation scheme under which the company’s senior employees can take unlimited paid leaves annually. As per sources, the global investment bank has unveiled a new policy that will allow senior sta...

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...